P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data

Detalles Bibliográficos
Autores principales: Driessen, Julia, De Wit, Fer, Herrera, Alex F., Zinzani, Pier Luigi, Lacasce, Ann S., Cole, Peter D., Moskowitz, Craig H., Sanz, Ramón. García, Fuchs, Michael, Müller, Horst, Borchmann, Peter, Santoro, Armando, Schöder, Heiko, Zijlstra, Josée. M., Hutten, Barbara A., Moskowitz, Alison J., Kersten, Marie José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Relapsed/Refractory
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642058/
http://dx.doi.org/10.1097/01.HS9.0000890996.84518.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642058/
http://dx.doi.org/10.1097/01.HS9.0000890996.84518.13

Ejemplares similares